Trade Blueprint Medicines Corporation - BPMC CFD

Trading Conditions

• Spread: 0.38
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 90.61
• Open: 90.75
• 1-Year Change: 85.93%
• Day's Range: 90.75 - 94.66

Blueprint Medicines Corporation Company profile

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).